India to Russia: Albendazole Export Trade Route

To import Albendazole formulations into Russia, the product must be registered with Roszdravnadzor. The registration process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes quality, safety, and efficacy data. The standard timeline for product registration is 210 working days, excluding the duration required for clinical trials. The registration fee comprises an expert review fee and a certificate issuance fee, with the exact amounts varying based on the product's classification. Additionally, a Good Manufacturing Practice (GMP) inspection of the manufacturing facility is mandatory to ensure compliance with Russian GMP standards. This inspection is conducted by the State Institute of Drugs and Good Practices, under the Ministry of Industry and Trade.

Indian manufacturers exporting Albendazole formulations to Russia must hold a valid Russian GMP certificate, confirming adherence to Russian GMP standards (GOST R 52249-2009). The GMP certification process involves a thorough inspection of the manufacturing facility by Russian authorities. The GMP certificate is typically valid for 1 to 3 years. As of March 2026, Russia has transitioned to the Eurasian Economic Union (EAEU) GMP rules, requiring compliance with these unified standards. Indian facilities must undergo inspections to obtain EAEU GMP certification, which is valid for three years from the date of the last inspection. Recent inspections have focused on ensuring compliance with these updated standards, with increased scrutiny on manufacturing practices.

Between 2024 and 2026, several regulatory changes have impacted the import of pharmaceutical products into Russia:

• September 2024: The Ministry of Healthcare introduced amendments requiring manufacturers to confirm the quality of each batch of pharmaceutical substances with Roszdravnadzor. Applicants must submit drug samples and related documentation within 90 business days of a request.

• August 2024: The Ministry of Industry and Trade increased fees for inspecting pharmaceutical manufacturers for EAEU GMP compliance. Inspection fees for domestic companies rose by 100,000 rubles, and travel allowances for inspection commissions increased.

• March 1, 2026: Russia completed its transition to EAEU GMP rules, invalidating previous national GMP inspection regulations. Post-transition, inspections and GMP compliance certifications are conducted exclusively under EAEU standards.

These developments necessitate that Indian exporters ensure their manufacturing practices align with the updated EAEU GMP standards and remain vigilant about compliance with the evolving regulatory landscape in Russia.

In 2024, the Russian market for Albendazole formulations was valued at approximately $75 million, reflecting a steady demand for anthelmintic treatments. This demand is primarily driven by the prevalence of parasitic infections, particularly in rural areas, and the government's initiatives to improve public health through mass deworming programs. The Russian healthcare system's commitment to universal health coverage ensures that such essential medications are accessible to the population. While Russia has domestic pharmaceutical manufacturing capabilities, a significant portion of Albendazole formulations is imported to meet the total demand.

Pharmaceutical imports classified under HS code 30049099, including Albendazole formulations, are subject to a 0% import duty in Russia. Additionally, these imports are exempt from Value Added Tax (VAT), further reducing the cost burden on importers and consumers. There are no Free Trade Agreements (FTAs) between India and Russia that specifically affect pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on Albendazole formulations imported from India, allowing for competitive pricing in the Russian market.

India is a major supplier of Albendazole formulations to Russia, accounting for approximately 3.4% of India's total Albendazole formulation exports, valued at $2.5 million USD across 11 shipments from three Indian manufacturers/exporters. The top Indian exporters include IPCA Laboratories Limited and Oxford Laboratories Private Limited. In Russia, the primary buyers are Hincus Pharmaceuticals and OOO Pharmvysota. Other countries supplying Albendazole formulations to Russia include China and various European Union manufacturers. India's pricing for Albendazole formulations is competitive, often undercutting European manufacturers due to lower production costs, while maintaining quality standards that meet Russian regulatory requirements.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's supply by volume. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are certified by international regulatory bodies such as the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the U.S. Food and Drug Administration (FDA). This extensive infrastructure enables the large-scale production of finished dosage forms containing Albendazole, including tablets, capsules, and syrups.

The cost structure of Indian pharmaceutical manufacturing is highly competitive, attributed to factors such as lower labor costs, economies of scale, and a well-established supply chain for raw materials. These advantages allow Indian manufacturers to offer Albendazole formulations at prices that are often more affordable than those from other regions. As of 2024-2025, numerous Indian facilities producing Albendazole formulations have received WHO-GMP and FDA approvals, ensuring compliance with stringent international quality standards.

When comparing Albendazole formulation exports, India offers a compelling balance of cost and quality. Chinese manufacturers are known for their cost-effective production; however, concerns regarding quality control and regulatory compliance have been raised in certain markets. European Union (EU) manufacturers are recognized for high-quality, branded generics but often at higher price points due to stringent regulatory requirements and higher production costs.

In the Russian market, Indian Albendazole formulations are well-regarded for their quality and affordability. Indian manufacturers have a strong track record of regulatory compliance and supply reliability, making them preferred partners for Russian buyers seeking cost-effective and high-quality pharmaceutical products.

The India-Russia supply chain for Albendazole formulations has demonstrated reliability, supported by India's substantial manufacturing capacity and advanced packaging capabilities. Indian facilities are equipped to produce large volumes of finished dosage forms, ensuring consistent supply to international markets. Packaging and cold chain logistics are well-developed, maintaining product integrity during transit.

Recent developments indicate ongoing investments in manufacturing infrastructure. For instance, in November 2025, Granules India Limited announced that its subsidiary, Granules Life Sciences Private Limited, received U.S. FDA approval for a product manufactured at its Hyderabad facility, marking a significant milestone in expanding finished dosage manufacturing capabilities. This approval underscores the facility's compliance with international quality standards and its readiness to meet global demand.

Additionally, in September 2024, Alembic Pharmaceuticals Limited received final approval from the U.S. FDA for its Albendazole Tablets USP, 200 mg. This approval reflects the company's commitment to maintaining high manufacturing standards and its capacity to supply quality Albendazole formulations to international markets.

These developments indicate that leading Indian manufacturers are actively enhancing their production capacities and maintaining compliance with international regulatory standards, ensuring a stable and reliable supply of Albendazole formulations.

For Russian buyers sourcing Albendazole formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Be aware that Indian manufacturers may have MOQs ranging from 100,000 to 500,000 tablets per order. Negotiating MOQs based on demand forecasts can lead to more favorable terms.

• Payment Terms: Standard payment terms in India-Russia pharmaceutical trade often include a 30% advance payment with the balance payable upon shipment or delivery. Establish clear payment agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory certifications (such as WHO-GMP and FDA approvals), and assessment of quality control systems to ensure compliance with international standards.

• Regulatory Compliance: Ensure that selected suppliers have a strong track record of regulatory compliance and can provide necessary documentation to facilitate product registration and importation into Russia.

By implementing these strategies, Russian buyers can establish a robust and reliable supply chain for Albendazole formulations sourced from India.

By adhering to this comprehensive approach, Russian buyers can ensure the selection of reliable Indian suppliers for Albendazole formulations, maintaining product quality and regulatory compliance.